[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Friday Afternoon",
    "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt",
    "url": "https://finnhub.io/api/news?id=26499900e1001f4237930815b649ff63f8fc563f2b951ed39ab682bd1801eb33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772218889,
      "headline": "Sector Update: Health Care Stocks Higher Friday Afternoon",
      "id": 139255600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt",
      "url": "https://finnhub.io/api/news?id=26499900e1001f4237930815b649ff63f8fc563f2b951ed39ab682bd1801eb33"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents (ages 12 to <18) with severe alopecia areata (AA). AA is a chronic immune disease that can have an especially devastating social and emotional impact on young patients and their families, as early onset AA can be more severe and lead to",
    "url": "https://finnhub.io/api/news?id=5a22d64cea56d449882ee250a1f5ef3684c008211251611b7e216675ce0926d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772197860,
      "headline": "Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata",
      "id": 139247174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents (ages 12 to <18) with severe alopecia areata (AA). AA is a chronic immune disease that can have an especially devastating social and emotional impact on young patients and their families, as early onset AA can be more severe and lead to",
      "url": "https://finnhub.io/api/news?id=5a22d64cea56d449882ee250a1f5ef3684c008211251611b7e216675ce0926d4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly And Incyte Say EMA's CHMP Issues Positive Opinion For Olumiant For Treatment Of Adolescents With Severe Alopecia Areata",
    "summary": "The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeksThe study is the first",
    "url": "https://finnhub.io/api/news?id=17d1d9d5e62292cccaf9a4a0b469578da98e2c16e1bf6d7bdcd591afb3ce098d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772183633,
      "headline": "Eli Lilly And Incyte Say EMA's CHMP Issues Positive Opinion For Olumiant For Treatment Of Adolescents With Severe Alopecia Areata",
      "id": 139246613,
      "image": "",
      "related": "INCY",
      "source": "Benzinga",
      "summary": "The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeksThe study is the first",
      "url": "https://finnhub.io/api/news?id=17d1d9d5e62292cccaf9a4a0b469578da98e2c16e1bf6d7bdcd591afb3ce098d"
    }
  }
]